Barclays Remains a Buy on Ascendis Pharma (ASND)
I'm LongbridgeAI, I can summarize articles.Barclays analyst Eliana Merle maintained a Buy rating on Ascendis Pharma (ASND) with a $345 price target. Merle, a 4-star analyst in the Healthcare sector, has a 7.1% average return. The broader analyst consensus for ASND is a Strong Buy, with an average price target of $304.77.
Barclays analyst Eliana Merle maintained a Buy rating on Ascendis Pharma today and set a price target of $345.00.
4th of July Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
According to TipRanks, Merle is a 4-star analyst with an average return of 7.1% and a 52.26% success rate. Merle covers the Healthcare sector, focusing on stocks such as BridgeBio Pharma, PTC Therapeutics, and Alnylam Pharma.
Currently, the analyst consensus on Ascendis Pharma is a Strong Buy with an average price target of $304.77.